Regulation of p130cas/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2

Neoplasia

Volumn 14, Issue 2, 2012, Pages 108-120

  Kumbrink, Joerg ^a   Kirsch, Kathrin H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PEPTIDYLPROLYL ISOMERASE; RIBOSOME PROTEIN; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; COMPUTER MODEL; CONTROLLED STUDY; DENSITOMETRY; EXON; GENE CONTROL; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84858047927     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111760     Document Type: Article

References (53)

1. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y, and Hirai H (1994). A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 13, 3748-3756.
2. Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92, 112-120.
3. Dorssers LC, van Agthoven T, Dekker A, van Agthoven TL, and Kok EM (1993). Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 7, 870-878.
4. Singh MK, Dadke D, Nicolas E, Serebriiskii IG, Apostolou S, Canutescu A, Egleston BL, and Golemis EA (2008). A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell 19, 1627-1636.
5. Bouton AH, Riggins RB, and Bruce-Staskal PJ (2001). Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 20, 6448-6458.
6. Singh M, Cowell L, Seo S, O'Neill G, and Golemis E (2007). Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys 48, 54-72.
7. Tikhmyanova N, Little JL, and Golemis EA (2010). CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 67, 1025-1048.
8. Cabodi S, Pilar Camacho-Leal M, Di Stefano P, and Defilippi P (2010). Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10, 858-870.
9. Kumbrink J and Kirsch KH (2011). Targeting Cas family proteins as a novel treatment for breast cancer. In Breast Cancer- Current and Alternative Thera-peutic Modalities. E Gunduz and M Gunduz (Eds). InTech pp. 37-62.
10. Marcotte R and Muller WJ (2008). Signal transduction in transgenic mouse models of human breast cancer-implications for human breast cancer. J Mammary Gland Biol Neoplasia 13, 323-335.
11. Sotiriou C and Pusztai L (2009). Gene-expression signatures in breast cancer. N Engl J Med 360, 790-800.
12. 3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 24, 3759-3773.
13. Henderson BE and Feigelson HS (2000). Hormonal carcinogenesis. Carcinogenesis 21, 427-433.
14. Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 92, 120-127.
15. Konstantinovsky S, Smith Y, Zilber S, Tuft SH, Becker AM, Nesland JM, Reich R, and Davidson B (2010). Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol 2010, 969084.
16. Cas in canine and feline mammary tumors. Vet Res 34, 193-202.
17. Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, and Foekens JA (2001). Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61, 1721-1733.
18. Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res 68, 8796-8804.
19. Soni S, Lin BT, August A, Nicholson RI, and Kirsch KH (2009). Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells. J Cell Biochem 107, 364-375.
20. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, and Nicholson RI (2003). Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044.
21. Zhang Y, Su H, Rahimi M, Tochihara R, and Tang C (2009). EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer 125, 2021-2028.
22. Waf1/Cip1 gene transcription is mediated by early growth response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Cell Signal 19, 1290-1300.
23. Suzuki T, Inoue A, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, and Sasano H (2007). Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocr Relat Cancer 14, 279-292.
24. Thiel G and Cibelli G (2002). Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193, 287-292.
25. Carter JH, Lefebvre JM, Wiest DL, and Tourtellotte WG (2007). Redundant role for early growth response transcriptional regulators in thymocyte differentiation and survival. J Immunol 178, 6796-6805.
26. Beckmann AM and Wilce PA (1997). Egr transcription factors in the nervous system. Neurochem Int 31, 477-510.
27. Honkaniemi J, Zhang JS, Longo FM, and Sharp FR (2000). Stress induces zinc finger immediate early genes in the rat adrenal gland. Brain Res 877, 203-208.
28. Liu D, Evans I, Britton G, and Zachary I (2008). The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis. Oncogene 27, 2989-2998.
29. Khachigian LM, Williams AJ, and Collins T (1995). Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth-factor-A-chain promoter in cultured vascular endothelial-cells. J Biol Chem 270, 27679-27686.
30. Sevetson BR, Svaren J, and Milbrandt J (2000). A novel activation function for NAB proteins in EGR-dependent transcription of the luteinizing hormone beta gene. J Biol Chem 275, 9749-9757.
31. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, and Milbrandt J (1996). NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 16, 3545-3553.
32. Kumbrink J, Kirsch KH, and Johnson JP (2010). EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin. J Cell Biochem 111, 207-217.
33. Kumbrink J, Gerlinger M, and Johnson JP (2005). Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop. J Biol Chem 280, 42785-42793.
34. Thierry-Mieg D and Thierry-Mieg J (2006). AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 7(suppl 1), S12-S14.
35. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, and Werner T (2005). MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21, 2933-2942.
36. Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, and Sonenshein GE (2007). The tumor suppressor activity of the lysyl oxidase pro-peptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res 67, 1105-1112.
37. Kirsch KH, Georgescu MM, and Hanafusa H (1998). Direct binding of p130(Cas) to the guanine nucleotide exchange factor C3G. J Biol Chem 273, 25673-25679.
38. Kirsch KH, Korradi Y, and Johnson JP (1996). Mader: a novel nuclear protein over expressed in human melanomas. Oncogene 12, 963-971.
39. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408.
40. Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int J Cancer 89, 465-468.
41. Cas. Proc Natl Acad Sci USA 92, 10678-10682.
42. Svaren J, Sevetson BR, Golda T, Stanton JJ, Swirnoff AH, and Milbrandt J (1998). Novel mutants of NAB corepressors enhance activation by Egr transac-tivators. EMBO J 17, 6010-6019.
43. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, et al. (2006). Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12, 4533-4544.
44. Zhao HJ, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Karesen R, Botstein D, Borresen-Dale AL, et al. (2004). Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15, 2523-2536.
45. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, et al. (2005). The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 102, 11005-11010.
46. Kumahara E, Ebihara T, and Saffen D (1999). Nerve growth factor induces zif268 gene expression via MAPK-dependent and -independent pathways in PC12D cells. J Biochem 125, 541-553.
47. Wang H, Li R, and Hu Y (2009). The alternative noncoding exons 1 of aro-matase (Cyp19) gene modulate gene expression in a posttranscriptional manner. Endocrinology 150, 3301-3307.
48. Kos M, Reid G, Denger S, and Gannon F (2001). Minireview: genomic organization of the human ERα gene promoter region. Mol Endocrinol 15, 2057-2063.
49. Fromont G, Vallancien G, Validire P, Levillain P, and Cussenot O (2007). BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate 67, 268-273.
50. Cas is also a key player in prostate cancer. Nat Rev Cancer 11, 227.
51. Abdulkadir SA, Carbone JM, Naughton CK, Humphrey PA, Catalona WJ, and Milbrandt J (2001). Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum Pathol 32, 935-939.
52. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJ, et al. (2001). Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7, 101-107.
53. Ma J, Ren Z, Ma Y, Xu L, Zhao Y, Zheng C, Fang Y, Xue T, Sun B, and Xiao W (2009). Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-κB synergy. J Biol Chem 284, 34600-34606.